Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Serum AGES (Advanced Glycation End Products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.
Serum AGES (Advanced Glycation End Products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. The energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since AGES (Advanced Glycation End Products) gives information about the energy metabolism of the people.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| women with endometriosis | It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography. |
| |
| control | It consists of healthy women between the ages of 18-45 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Advanced Glycation End Products (AGEs) | Other | Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated. |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Advanced Glycation End Products (AGEs) levels in women with endometriosis | Serum Serum Advanced Glycation End Products (AGEs) levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group | 8 months |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of the relationship between serum Serum Advanced Glycation End Products (AGEs) level and endometriosis stage | By comparing the relation of serum Advanced Glycation End Products (AGEs) level with the stage of endometriosis, its relation with serum level in patients with advanced and early stage endometriosis will be examined. The possible effect of Advanced Glycation End Products (AGEs) on disease pathogenesis will be examined. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Women aged 18-45 diagnosed with endometriosis (surgery or ultrasound)
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pinar Yalcin Bahat | Istanbul | İ̇stanbul | 34000 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017127 | Glycation End Products, Advanced |
| ID | Term |
|---|---|
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 8 months |
| D000091662 | Genital Diseases |